DLL3 and non-small cell lung carcinoma: Novel targets such as Bcl-2, VEGF, and delta-like protein 3 (DLL3) are currently being investigated in small cell lung cancer, which, if successful, may be applied to non-small-cell lung cancers [43, 44].